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Open access under CC BA rat respiratory epithelial cell culture system for in vitro prediction of drug pulmonary absorption is cur-
rently lacking. Such a model may however enhance the understanding of interspecies differences in
inhaled drug pharmacokinetics by ﬁlling the gap between human in vitro and rat in/ex vivo drug perme-
ability screens. The rat airway epithelial cell line RL-65 was cultured on Transwell inserts for up to
21 days at an air–liquid (AL) interface and cell layers were evaluated for their suitability as a drug per-
meability measurement tool. These layers were found to be morphologically representative of the bron-
chial/bronchiolar epithelium when cultured for 8 days in a deﬁned serum-free medium. In addition, RL-
65 layers developed epithelial barrier properties with a transepithelial electrical resistance (TEER)
>300 O cm2 and apparent 14C-mannitol permeability (Papp) values between 0.5–3.0  106 cm/s; i.e., in
the same range as established in vitro human bronchial epithelial absorption models. Expression of P-gly-
coprotein was conﬁrmed by gene analysis and immunohistochemistry. Nevertheless, no vectorial trans-
port of the established substrates 3H-digoxin and Rhodamine123 was observed across the layers.
Although preliminary, this study shows RL-65 cell layers have the potential to become a useful in vitro
screening tool in the pre-clinical development of inhaled drug candidates.
 2012 Elsevier B.V. Open access under CC BY license.1. Introduction
The inhaled route for drug delivery has been exploited for direct
targeting of locally acting drugs since the 1950s (Barnes, 2009).
More recently, the lung has also become an attractive alternative
route for systemic delivery of compounds with poor oral bioavail-
ability (Ehrhardt et al., 2008). While the human colonic Caco-2 cell
line has been approved by the Food and Drug Administration (FDA)
for permeability screening of orally administered drugs, an eco-
nomical, ethical and high throughput model for absorption predic-
tion of candidate inhaled drugs has yet to emerge.
In vitromodels that have been employed for studying drug per-
meability, metabolism and toxicity in the bronchial epithelium in-
clude the Caco-2 cell line (Tronde et al., 2003), and the human
bronchial epithelial cell lines Calu-3 (Meaney et al., 1999; Foster
et al., 2000; Grainger et al., 2006), 16HBE14o- (Ehrhardt et al.,
2002; Forbes et al., 2003) and BEAS-2B (Sporty et al., 2008). Addi-olecular Sciences, University
, UK. Tel.: +44 115 84 66078;
.uk (C. Bosquillon).
Y license.tionally, commercially available normal human bronchial epithe-
lial (NHBE) cells have been assessed for permeability modelling
(Lin et al., 2007) and toxicity screening (Balharry et al., 2008).
Whilst interspecies variations in drug handling, pharmacoki-
netic and safety proﬁles are well recognised, in vivo animal data
are required for regulatory approval of inhaled drugs, with the
rat being the most commonly used species due to size and ethical
justiﬁcations (Sakagami, 2006). Correlations between Caco-2
(Tronde et al., 2003), Calu-3 (Mathias et al., 2002) or 16HBE14o-
(Manford et al., 2005) permeability data and absorption parame-
ters in rat in vivo or isolated perfused lung (IPL) have been
established for a limited number of drug compounds. However, in-
stances where drug permeability in human respiratory cell culture
systems failed to model rat in/ex vivo pulmonary absorption have
been reported (Manford et al., 2005; Madlova et al., 2009).
The role of transmembrane transporters in drug disposition in
the intestine, liver, kidney or brain is becoming increasingly recog-
nised (Ayrton and Morgan, 2008). Amongst transporters present in
the lungs (Bleasby et al., 2006), P-glycoprotein (P-gp, MDR1) and
the organic cation/carnitine transporters (OCT and OCTN) have
been detected in the human bronchial epithelium (Bosquillon,
2010). Although the inﬂuence of lung transporters on drug
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mediated transport of inhaled therapeutic compounds in bronchial
epithelial cell culture models has been suggested (Ehrhardt et al.,
2005; Nakamura et al., 2010; Mukherjee et al., 2012).
On the other hand, there is considerable debate regarding the
impact of P-gp on drug disposition in the lungs. Functional studies
in rat models have demonstrated negligible transporter-mediated
absorption of P-gp substrates either ex vivo (Tronde et al., 2003;
Madlova et al., 2009) or in vivo (Manford et al., 2005). In contrast,
Francombe and colleagues have reported an increase in Rhoda-
mine123 (Rh123) absorption from rat IPL in the presence of the
P-gp potent inhibitor GF120918 in both the instillate and perfusate
solutions (Francombe et al., 2008). Similarly, studies that have
investigated the functionality of P-gp in human bronchial epithe-
lial cell layers are conﬂicting (Bosquillon, 2010). Due to possible
variations in substrate afﬁnity for the human or rat transporters,
a reliable assessment of P-gp involvement in pulmonary drug
absorption might only be achieved through a combination of in/
ex vivo data in rats and in vitro permeability measurements in both
human and rat airway epithelial cell layers.
An in vitro model of the rat respiratory epithelium would assist
in the evaluation of the role of transporters as well as interspecies
discrepancies in inhaled drug permeability. Importantly, bias in
in vitro/in vivo absorption correlations resulting from transporter
heterology, variable substrate speciﬁcity and different pulmonary
expression patterns in humans and rats would be minimised. This
could improve the reliability of in vitro prediction and thus, guide
the selection of drug candidates that progress to the late stages
of pre-clinical development. Although a rat airway cell culture
model is unlikely to replace drug testing in animals in the short
term, it may nevertheless help reduce and reﬁne the experimenta-
tion required.
RL-65 is a rat airway (bronchial/bronchiolar) epithelial cell line
that was isolated from 5 day old Sprague–Dawley rats (Roberts
et al., 1990). This has been exploited to investigate cell-signalling
pathways (Van Putten et al., 2001; Blaine et al., 2001; Wick et al.,
2005; Bren-Mattison et al., 2005; Nemenoff et al., 2008) or the epi-
thelial–mesenchymal transition (Wang et al., 2009; Felton et al.,
2011) in airway epithelial cells preferentially to other cell lines
due its non-cancerous origin and spontaneous immortalisation.
However, to date, the potential of RL-65 layers as an in vitro model
for pre-clinical drug screening has not been assessed. In addition,
although the cell line has recently been successfully grown on
Transwell cell culture inserts (Wang et al., 2009), its ability to
form layers morphologically similar to the native upper airway
epithelium at an air–liquid (AL) interface, as described for Calu-3
(Grainger et al., 2006) and NHBE (Lin et al., 2007) cells, has not
yet been demonstrated.
Here, we report the optimisation of RL-65 cell culture condi-
tions on Transwell inserts at an AL interface. The morphology
and barrier properties of cell layers grown in two different media
were characterised. Additionally, expression of selected drug trans-
porters was quantiﬁed and P-gp functionality investigated in the
model. This study provides an initial appraisal of the suitability
of AL interfaced RL-65 layers for ﬁlling the current gap between
rat ex/in vivo and human in vitro absorption models in pre-clinical
drug development.2. Materials and methods
2.1. Cell culture
The RL-65 cell line was obtained from the ATCC (Rockville, MD,
USA) and used for experiments between passage numbers 3 and 17
from purchase. Cells were cultured in 75 cm2 ﬂasks using a serum-free medium composed of Dulbecco’s modiﬁed Eagle’s medium/
Ham’s F12 nutrient mixture (DMEM/Ham F12) 1:1, supplemented
with 85 nM selenium, 2.5 lg/ml bovine insulin, 5.4 lg/ml human
transferrin, 30 lM ethanolamine, 100 lM phosphoethanolamine,
500 nM hydrocortisone, 5 lM forskolin, 50 nM retinoic acid and
0.15 mg/ml bovine pituitary extract (Sigma–Aldrich, Poole, UK).
Medium was exchanged thrice weekly and cells were passaged
when 90% conﬂuent using a 1:20 split ratio. Calu-3 cells were pur-
chased from the ATCC, used between passages 25–30 and cultured
as outlined previously by Madlova et al. (2009). Normal human pri-
mary bronchial epithelial (NHBE) cells were purchased from Lonza
(Slough, Berkshire, UK) and cultured (passage 2) using the Lonza
proprietary B-ALI kit according to the manufacturer’s
instructions.
RL-65 cells were seeded at a density of 1  105 cells/cm2 on
0.4 lm pore size, 1.13 cm2 polyester Transwell cell culture sup-
ports (Corning Costar, High Wycombe, UK) and cultured in sub-
merged (LL) conditions or raised at an air–liquid (AL) interface
after 24 h. The cell culture medium was either that outlined above
with the addition of 100 IU/ml penicillin and 100 lg/ml strepto-
mycin antibiotic solution (herein referred to as serum free medium
(SFM)) or an alternative serum containing medium (SCM) compris-
ing DMEM/Ham F12 (1:1) supplemented with 10% v/v fetal bovine
serum (non-USA origin, Sigma), 100 IU/ml penicillin and 100 lg/ml
streptomycin antibiotic solution, 2 mM L-glutamine and 1% v/v
non-essential amino acids (all from Sigma). For LL culture, the api-
cal and basolateral compartments of the Transwell contained
0.5 ml or 1.5 ml of medium, respectively. For AL culture, 0.5 ml of
medium was added to the basolateral chamber only. The medium
was subsequently replaced in respective compartments on alter-
nate days.
NHBE cells were harvested once they reached 90% conﬂuence
using the supplier’s subculture reagents (Lonza) and seeded onto
0.4 lm pore size, 0.33 cm2 polyester Transwell inserts previously
coated with rat tail collagen type I (BD Biosciences, Oxford, Oxford-
shire, UK) at a density of 1.5  105 cells/cm2. After 72 h, they were
raised to an AL interface and cultured in the supplier’s differentia-
tion medium (Lonza) for 21 days. Thereafter, the medium was
changed every 2–3 days.
2.2. Trans-epithelial electrical resistance (TEER) measurements
The TEER was recorded using an EVOM volt–ohm–meter with
STX-2 chopstick electrodes (World Precision Instruments, Steve-
nage, UK). Measurements on cells in LL culture were taken imme-
diately before the mediumwas exchanged. For cells cultured at the
AL interface, 0.5 ml and 1.0 ml of medium was added to the apical
and basolateral chambers, respectively. Cells were returned to the
incubator to equilibrate for at least 20 min before TEER was mea-
sured. TEER values reported were corrected for the resistance
and surface area of the Transwell ﬁlters.
2.3. Histological preparation and staining
Cells were ﬁxed on the Transwell membrane using 3.7% w/v
paraformaldehyde in PBS for 15 min at room temperature. The ﬁx-
ing solution was removed and cell layers were stored submerged in
PBS at 4 C until processed. For histology preparation, ﬁlters were
excised from the inserts and sandwiched between two biopsy foam
pads inside a histology cassette. Samples were subjected to 5 min
incubations in increasing concentrations of ethanol in dH2O (25,
50, 75, 90, 95, 100% v/v), followed by two 5 min exposures to xy-
lene and a 30 min treatment in parafﬁn wax. Dehydrated samples
were embedded in wax and 6 lm thick cross-sections cut using a
RM 2165 rotary microtome (Leica, Milton Keynes, UK) before being
mounted on poly-L-lysine coated histology slides. Cellular cross-
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in decreasing concentrations of ethanol in dH2O (100, 95, 90, 75,
50, 25% v/v) for 2 min each. Slides were then immersed in 100%
dH2O before histological staining. All incubation steps for histolog-
ical staining were performed at room temperature.
For morphological staining, slides were immersed in Mayer’s
haematoxylin stain for 10 min and excess stain removed by rinsing
for 2 min in dH2O. Samples were then submerged for 2 min in
Scott’s tap water (3.5 g sodium bicarbonate, 20 g magnesium sul-
phate in 1 L dH2O) before incubation in 1% v/v eosin in dH2O for
5 min. For mucus staining, samples were submerged in a 1% w/v al-
cian blue in 3% v/v acetic acid pH 2.5 for 5 min. Excess stain was
removed with a 2 min dH2O wash before incubation in neutral fast
red for 5 min. For both types of staining, the samples were rinsed in
dH2O until the colour ran clear and ﬁnally, mounted with glycerol
on cover slips for imaging.2.4. Scanning electron microscopy
Cells were ﬁxed in a 1:1 mixture of medium and ﬁxing solution
(2.5% v/v glutaraldehyde in 0.1 M sodium cacodylate buffer, pH
7.2) which was added to both apical and basolateral chambers of
the Transwell. After 5 min, the solution was removed and re-
placed with 2.5% v/v gluteraldehyde ﬁxing solution and samples
were stored at 4 C for up to 2 weeks.
For scanning electron microscopy (SEM) processing, all ﬁxing
solution was aspirated from both chambers of the Transwell
and 1% w/v osmium tetroxide in PBS added to both compartments.
After 90 min, the solution was removed and rinsed ﬁve times with
PBS before dehydration in progressively increasing concentrations
of ethanol in dH2O (25%, 50%, 75%, 95% and 100%). Samples were
critically point dried with CO2 using an EM CPD030 (Leica, Milton
Keynes, UK) and ﬁlters were removed and mounted on aluminium
stubs with adhesive carbon tape. The samples were gold coated for
5 min using a sputter coater SCD030 unit (Balzers Union, Milton
Keynes, UK) under an argon atmosphere and analysed with a
SEM 6060LV unit (JOEL, Welwyn, UK) at an accelerating voltage
of 30 kV and stage height of 10 mm.2.5. Immunoﬂuorescence microscopy
All medium was aspirated from the Transwell and cells were
washed twice with PBS at pH 7.4. Samples were ﬁxed for 15 min
using 500 ll of 3.7% w/v paraformaldehyde in the apical chamber.
After the elapsed time, paraformaldehyde was removed and PBS
added to both chambers. Fixed samples were stored up to 14 days
at 2–8 C prior to analysis.
Fixed cell layers were permeabilized with 0.1% v/v Triton X-
100 in PBS for 5 min and rinsed in PBS. Samples were blocked
for 30 min with 1% w/v bovine serum albumin (BSA) in PBS and
incubated with 10 lg/ml mouse anti-zonula occludens (zo-1)
monoclonal antibody (Invitrogen, Paisley, UK) or 20 lg/ml UIC2
mouse anti-mdr1 (Enzo Life Science, Exeter, UK) monoclonal anti-
body or a mouse anti-b-tubulin IV monoclonal antibody (Sigma)
at a 1:500 dilution for 60 min at 37 C. Cells were washed in 1%
w/v BSA in PBS before incubation with FITC-labelled goat anti-
mouse IgG (1:64) (Sigma) in PBS for a further 30 min at room
temperature. Cell nuclei were counter-stained with propidium io-
dide (PI) 1 lg/ml in PBS for 30 s. Inserts were washed with PBS
and the ﬁlter was excised and mounted on a slide using DABCO
anti-fade mounting media (all from Sigma). Samples were imaged
by a Meta 510 confocal microscope (Zeiss, Welwyn Garden City,
UK) with excitation at a wavelength of 488 nm and 543 nm
and emission observed at 519 nm and 617 nm for FITC and PI,
respectively.2.6. Gene expression analysis
RL-65 cells were harvested from Transwell inserts on the day
functional experiments were performed. Cells were washed once
with PBS, ﬁlters were excised and snap frozen in liquid nitrogen
before transferral to 80 C storage until processing. For mRNA
isolation, 1.2 ml RNA STAT-60 (Tel-test, Friendswood, TX) was
added to 12 excised ﬁlters and the samples were processed accord-
ing to the manufacturer’s protocol. RNA preparations were
assessed for quantity and purity using a Nanodrop ND-1000-UV–
Vis spectrophotometer (Nanodrop Technologies, Wilmington,
USA). Integrity of the RNA preparation was assessed by the pres-
ence of distinct 18S and 28S bands on a 1% w/v agarose gel using
a Tris borate-EDTA buffer (0.09 M Tris borate, 2 mM EDTA, pH
7.8) at 90 mV for 60 min.
cDNA was prepared from 2 lg of total RNA using the Super-
script™ First-Strand Synthesis System (Invitrogen, Paisley, UK)
with random hexamer primers according to the manufacturer’s
protocol. Samples were incubated at 65 C for 5 min then held on
ice for 1 min before the addition of Superscript III reverse trans-
criptase. Samples were then incubated at 25 C for 10 min followed
by reverse transcription at 50 C for 50 min. The reaction was ter-
minated by heating to 85 C for 5 min to inactivate the enzyme.
Quantitative PCR was carried out on a 7500 Real Time PCR Se-
quence Detection System (Applied Biosystems, Foster City, CA).
TaqMan analysis was performed in a 25 ll reaction mixture con-
taining 30 ng cDNA, TaqMan Universal PCR Master Mix (compris-
ing AmpliTaq Gold DNA polymerase, dNTPs with dUTP, passive
reference and optimised buffer) and Assay-on-demand™ gene
expression assay mixes containing speciﬁc primers and probes
(all from Applied Biosystems). The PCR conditions comprised a
2 min incubation at 50 C followed by a 10 min polymerase activa-
tion at 95 C. This was followed by 40 cycles alternating between
95 C for 15 sections and 60 C for 1 min each.
Ampliﬁcation curves were analysed using the SDS version 3.2
software (Applied Biosystems, Foster City, CA). The baseline and
threshold values were set and the Ct values extracted for each gene
of interest. Relative quantiﬁcation was calculated using the geo-
metric mean of two selected house-keeping genes, gapdh and
mvp. Relative gene expression levels were calculated using the
equation 2DCt. An arbitrary classiﬁcation system was applied to
the data quantifying relative expression levels as ‘high’ >0.5, ‘mod-
erate’ between 0.02 and 0.5, ‘low’ between 0.001–0.02 and ‘negli-
gible’ <0.001.
2.7. Transport studies
All transport experiments were conducted in standard buffer
solution (SBS) comprising Hank’s Balanced Salt Solution (HBSS)
supplemented with 20 mM 4-(2-hydroxyethyl)-1-piperazinee-
thanesulfonic acid (HEPES). Cell layers were allowed to equilibrate
in SBS for 60 min at 37 C before TEER measurements were taken.
Each condition was carried out in quadruplicate and only layers
with a resistance >250X cm2 were accepted for experimentation.
For transport studies with radiolabelled markers, donor compart-
ments were ﬁlled with 0.51 ml (apical to basolateral (AB) trans-
port) or 1.51 ml (basolateral to apical (BA) transport) of SBS
containing 25 nM 3H-digoxin and/or 6.55 lM 14C-mannitol. Recei-
ver compartments were ﬁlled with 1.5 ml (AB transport) or 0.5 ml
(BA transport) of SBS. At the start and end of the experiment, 10 ll
samples were taken from the donor compartments for determina-
tion of the initial and ﬁnal concentration. Every 30 min over a 2 h
period, 300 ll samples (AB transport) and 100 ll samples (BA
transport) were taken from the respective receiver chambers and
replaced with the same volume of SBS. Cells were maintained at
37 C and rotated at 60 rpm on an orbital shaker throughout the
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kin Elmer, Cambridge, UK) was added to each sample and radioac-
tivity determined in a Wallac 1409 liquid scintillation counter
(Wallac, Turku, Finland).
For permeability assessment of the ﬂuorescent dye Rhoda-
mine123 (Rh123), experiments were set up similarly to radioactive
transport experiments outlined above with the donor solution
comprising 5 lM Rh123 in SBS. Every 30 min for a 2 h period,
100 ll samples were taken from the receiver chambers and ana-
lysed neat. The 10 ll samples from the donor wells were diluted
1:99 with SBS and 100 ll of this used for analysis. All samples were
transferred to a black 96 well plate and analysed at an excitation
wavelength of 485 nm and emission wavelength of 538 nm using
an Inﬁnite M200 PRO spectrophotometer (Tecan, Reading, UK).
The Rh123 concentration in each sample was determined from a
calibration curve.
Apparent permeability coefﬁcients (Papp) were calculated using
the following equation: Papp ¼ dQ=dtAC0 where dQ/dt is the ﬂux of the
substrate across the cell layer, A is the surface area of the ﬁlter
and C0 is the initial concentration of the substrate in the donor
solution.2.8. Statistics
For all TEER and permeability data generated, results were ex-
pressed as mean ± SD. Datasets with nP 5 were assessed for nor-
mality and the data ﬁtted a normal (Gaussian) distribution.
Therefore normality was assumed for all datasets where n < 5
and each were compared using a two-tailed, unpaired Student’s
t-test with Welch correction applied (to consider unequal variance
between datasets). Statistical signiﬁcance was evaluated at a 99%
conﬁdence level (p < 0.01). All statistical tests were performed
using GraphPad InStat version 3.06.Fig. 1. Inﬂuence of the culture medium on TEER development in RL-65 layers
maintained in (A) SFM and (B) SCM at an air–liquid interface (AL) or under
submerged conditions (LL). Data are represented as mean ± SD (n = 4–6 cell layers).3. Results
3.1. Barrier properties of RL-65 cell layers
The barrier properties of RL-65 cell layers were assessed by
TEER measurements, expression of the tight junction protein zo-
1 and permeability of the paracellular marker 14C-mannitol. TEER
was measurable from day 4 after seeding for RL-65 cells cultured
in both media (Fig. 1). At passage 3, cells cultured in SFM either
at an AL interface or under submerged conditions displayed a sim-
ilar TEER proﬁle with maximal TEER between days 8 to 10 in cul-
ture. Thereafter, this steadily declined to <100 O cm2 at day 18 in
culture, when cells had detached from the ﬁlters (Fig. 1A). At day
8 in SFM, cell layers cultured at the AL interface produced signiﬁ-
cantly higher (p > 0.01) TEER values (667 ± 65 O cm2) compared
with their submerged culture counterparts (503 ± 50 O cm2). At la-
ter passages, (passages 6, 9 and 12) maximal TEER values after
8 days in culture were 200–400 O cm2 (data not shown), in agree-
ment with TEER values obtained by Wang and co-workers (Wang
et al., 2009). The TEER proﬁle for submerged RL-65 cell cultures
maintained in SCMwas similar to that in SFM. However, when cells
were cultured at an AL interface, TEER values steadily increased to
reach a plateau 400–600 O cm2 after 10 days in culture which
was maintained until the end of the 22 day monitoring period
(Fig. 1B). Based on these TEER values, RL-65 cell layers were further
characterised at the AL interface after 8 days in SFM and 8 and
21 days in SCM.
Immunocytochemistry experiment on RL-65 layers cultured at
the AL interface for 8 days in both media showed a positive stain-
ing for the zo-1 protein along the cell perimeter, in agreement with
the location of tight junction proteins (Fig. 2).14C-mannitol permeability studies resulted in Papp values rang-
ing from 0.54 ± 0.11 to 3.09 ± 0.36  106 cm/s, depending on the
conditions and length in culture (Table 1). Those were in the same
range as in-house and published Papp obtained in existing human
bronchial epithelial cell culture models (Table 1). After 8 days at
an AL interface, 14C-mannitol Papp values were signiﬁcantly lower
in RL-65 layers grown in SCM than in layers maintained in SFM,
in agreement with the higher TEER achieved in SCM. As previously
reported for the Calu-3 and 16HBE14o- cell lines (Forbes et al.,
2003; Sakagami, 2006), a strong inverse correlation (R = 0.9658)
with power regression was indeed found between TEER and 14C-
mannitol Papp values in RL-65 layers (Fig. 3).
3.2. RL-65 cell layer morphology
The morphology of RL-65 layers was characterised using histo-
logical and SEM examinations. Cross-sections of RL-65 cell layers
cultured in SFM for 8 days depicted 2–3 layers of cuboidal cells
similar to that observed for sections of NHBE cells maintained at
an AL interface for 21 days (Fig. 4A and D). In contrast, RL-65 cells
cultured in SCM for 8 days formed a viable layer 1–3 cells thick
adjacent to the ﬁlter underneath a 5 lm thick layer of pink/pur-
ple eosin stained material containing no viable cells (Fig. 4B). After
21 days, the non-viable apical substance had extended to a
30 lm thick stratum and viable RL-65 cells formed a ﬂatter single
layer adjacent to the ﬁlter (Fig. 4C). Alcian blue staining failed to
show the presence of mucopolysaccharides at the surface of RL-
65 cell layers while positive staining was observed apically in
Fig. 2. Confocal laser scanning microscopy of RL-65 cell layers immunolabelled for
the tight junction protein zo-1 (green). Cells were cultured in (A) SFM or (B) SCM for
8 days at an air–liquid interface and counterstained with propidium iodide (red).
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
Table 1
Comparison of apparent permeability coefﬁcients (Papp) for the paracellular marker
14C-mannitol in different in vitro bronchial epithelial cell models cultured at the air–
liquid interface. Data are represented as mean ± SD of 8 inserts for RL-65 cells and 20
inserts for Calu-3 and NHBE cell layers (in house data).
Cell type Days in culture 14C-Mannitol Papp (1  106 cm/s)
Calu-3 21 0.49 ± 0.23
NHBE 21 0.55 ± 0.13
16HBE14o-a 7 2.36 ± 0.66
RL65 (SFM) 8 3.09 ± 0.36
RL65 (SCM) 8 1.29 ± 0.16
RL65 (SCM) 21 0.54 ± 0.11
a Values were taken from the literature Forbes et al. (2003).
Fig. 3. Relationship between TEER value and 14C-mannitol apparent permeability in
RL-65 cell layers. Cells were cultured at the AL interface in SCM or SFM for either 8
or 21 days.
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RL-65 apical surface revealed a heterogeneous cell population
(Fig. 5A). At closer magniﬁcation, small cylindrical appendages,
2 lm in length and <0.5 lm in diameter were observed protrud-
ing from the apical cell surface of RL-65 cells cultured in SFM, sug-
gesting the presence of microvilli or immature cilia (Fig. 5B). This
assumption was supported by a localised positive immunohisto-
chemical staining for the cilia marker b-tubulin at the surface of
the layers (Fig. 5C).3.3. Expression and functionality of drug transporters in RL-65 layers
Gene expression analysis of selected transporters revealed sim-
ilar relative mRNA levels in RL-65 cells cultured for 8 days in either
SFM or SCM. Expression levels were negligible (<0.001) for abcb1a
(mdr1a), abcc2 (mrp2), slc22a1-3 (oct1-3) whilst a low (0.001–
0.02) or moderate (0.02–0.5) expression was observed for abcb1b
(mdr1b) and slca5 (octn2), respectively (Table 2).
The presence and functionality of P-gp (mdr1) proteins were
probed respectively by immunocytochemistry and bi-directional
permeability studies with the two established substrates, 3H-
digoxin and Rh123. A positive immunocytochemical signal was ob-
tained on the apical surface of RL-65 cell layers cultured in both
media for 8 days while no green ﬂuorescence was detected when
cells were only incubated with the FITC-labelled secondary anti-
body (Fig. 6). However, no statistical difference (p > 0.05) between
AB and BA transport across 8-day old RL-65 layers was observed
for any of the two P-gp substrates investigated (Fig. 7), suggesting
negligible transporter-mediated drug trafﬁcking in the cell culture
model.4. Discussion
In vivo and ex vivo absorption studies are frequently conducted
in rats to predict the pharmacokinetics of inhaled drug candidates
in humans (Tronde et al., 2003). However, variations in drug dispo-
sition in human and rat lungs have yet to be fully appraised. A rat
respiratory epithelial cell culture model suitable for permeability
screening would aid better understanding of interspecies differ-
ences in pulmonary drug absorption, including the role of drug
transporters, in addition to providing an ethical alternative to ani-
mal testing.
This study evaluates the potential of layers of the bronchial/
bronchiolar epithelial rat cell line, RL-65, as an in vitro permeability
screening tool. It demonstrates that RL-65 cells cultured at an AL
interface on Transwell supports formed layers morphologically
similar to the upper airway epithelium with a TEER and 14C-man-
nitol paracellular permeability values in agreement with those in
established human bronchial epithelial cell models. Expression of
the drug transporters P-gp and octn2 was conﬁrmed in the cell lay-
ers, although no vectorial transport of widely used P-gp probes was
observed. This preliminary characterisation of air-interfaced RL-65
cell layers identiﬁes a potentially useful tool for investigating dif-
ferences in drug permeability between the human and rat airway
epithelia.
Morphological analysis of RL-65 cells grown in presence of ser-
um revealed multilayered cultures with an uppermost layer of
non-viable cells (Fig. 4), thus providing a poor representation of
the native epithelium. This indicated that a serum containing med-
ium is unsuitable for the development of RL-65 cells into polarised
layers mimicking the airway epithelium. Likewise, sub-optimal
growth of the cell line had previously been described in presence
of serum (Roberts et al., 1990). Our study also demonstrated that
the sole consideration of markers of epithelial barrier formation
such as TEER and paracellular permeability values is potentially
Fig. 4. Haematoxylin and eosin histological staining of 6 lm cross-sections of (A–C) RL-65 and (D) 21 day old air-interfaced NHBE cell layers. RL-65 cells were cultured at an
AL interface in (A) SFM for 8 days or SCM for (B) 8 days or (C) 21 days. All images are orientated with the apical cell surface closest to the top of the image.
Fig. 5. Characterisation of the apical cell surface of RL-65 cell layers cultured at an
AL interface for 8 days in SFM. (A and B) Scanning electron microscopy (SEM)
images at 230 or 4000 magniﬁcation, respectively. (C) Immunohistological
staining for the cilia marker b-tubulin (green). Cell nuclei were counterstained with
propidium iodide (red). (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
Table 2
Gene expression of selected ATP binding cassette (ABC) and solute-linked carrier
(SLC) transporters in RL-65 cell layers cultured at an air–liquid interface for 8 days in
either SFM or SCM. Relative gene expression levels are described as  : <0.001
(negligible), +: 0.001–0.02 (low), ++: 0.02–0.5 (moderate), +++: > 0.5 (high), relative to
gapdh and mvp. N/A: data not available.
Gene Protein SFM SCM Assay ID Sequence Accession ID
mvp lrp +++ +++ Rn00575634_m1 NM_022715
gapdh gapdh +++ +++ Rn01775763_m1 NM_017008
abcb1a mdr1a   Rn01639253_m1 NM_133401
abcb1b mdr1b + + Rn00561753_m1 NM_012623
abcc2 mrp2   Rn00563231_m1 NM_012833
slc22a1 oct1   Rn00562250_m1 NM_012697
slc22a2 oct2   Rn00580893_m1 NM_031584
slc22a3 oct3   Rn00570264_m1 NM_062183
slc22a4 octn1 N/A N/A  
slc22a5 octn2 ++ ++ Rn00570533_m1 NM_019269
Fig. 6. Confocal scanning microscopy of RL-65 cell layers immunolabelled for P-
glycoprotein (green). Cells were cultured for 8 days at an air–liquid interface in
either (A and B) SFM or (C and D) SCM. Figures (A and C) show the secondary
antibody controls. Cell nuclei were counterstained with propidium iodide (red). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
486 V. Hutter et al. / European Journal of Pharmaceutical Sciences 47 (2012) 481–489misleading for a reliable assessment of cell-based absorption
screens, and highlights the importance of morphological examina-
tions in the characterisation of those models.
In contrast, RL-65 cells maintained in a deﬁned serum-free
medium for 8 days produced cultures displaying 1–3 layers of
cuboidal cells, similar to normal human bronchial cells (Fig. 4).However, the possible presence of ciliated cells in absence of
detectable mucus secretions might suggest a bronchiolar origin
Fig. 7. Apical to basolateral (AB) and BA transport of (A) 3H-digoxin and (B) Rh123
across 8 day old RL-65 cell layers grown in SFM or SCM. Data are represented as
mean ± SD (n = 4–6 cell layers).
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600 O cm2 (Fig. 1), i.e., in the same range as Calu-3 (Borchard
et al., 2002; Fiegel et al., 2003), 16HBE14o- (Forbes et al., 2003)
and NHBE (Lin et al., 2007; Madlova et al., 2009) layers. 14C-man-
nitol permeability across the layers was measured as
3.0  106 cm/s (Table 1). Although higher than reported for
Calu-3 (Forbes and Ehrhardt, 2005) and NHBE (Madlova et al.,
2009) cell layers, this value is comparable to paracellular transport
data published in 16HBE14o- layers (Ehrhardt et al., 2002; Forbes
et al., 2003). RL-65 layers at an early passage (3–4) achieved higher
TEER values than at a later passage (6–18), suggesting an alteration
in barrier properties with increasing passage number. A similar
trend has also been reported for NHBE cell layers which lose
the ability to form a permeability barrier after 3–4 passages
(Widdicombe et al., 2005). In comparison to NHBE cells, the RL-
65 cell line nevertheless provides an extended passage window
for use in drug permeability measurements.
Gene expression analysis of selected drug transporters revealed
the presence of octn2 and mdr1b in RL-65 cell layers (Table 2). This
is in agreement with the high expression of OCTN2 in the human
bronchial epithelium (Horvath et al., 2007) and the higher levels
of mdr1b as compared to mdr1a transcripts detected in rat lungs
(Brown et al., 1993; Brady et al., 2002), respectively. Additionally,
apical expression of P-gp was conﬁrmed in RL-65 cell layers by
immunocytochemistry (Fig. 6), in accordance with its localisation
in rat bronchial epithelial tissue (Campbell et al., 2003). However,
no apparent efﬂux of 3H-digoxin and Rh123 was observed across
the layers (Fig. 7). As both compounds are substrates for the two
P-gp isoforms (mdr1a/b) found in rats (Schinkel et al., 1997;
Takeuchi et al., 2006; Suzuyama et al., 2007), our data suggests
the transporter was not functional in 8-day old RL-65 cell layers.The presence of functional P-gp in human bronchial epithelial
cell culture models remains controversial to date (Bosquillon,
2010). Several studies have concluded the transporter was respon-
sible for the apparent efﬂux of various substrates in NHBE,
16HBE14o- or Calu-3 cell layers (Lin et al., 2007; Ehrhardt et al.,
2003; Hamilton et al., 2001; Patel et al., 2002; Brillault et al.,
2009) while others have reported an absence of P-gp in Calu-3 lay-
ers (Cavet et al., 1997) or a negligible impact on drug transport in
the Calu-3 and NHBE models (Madlova et al., 2009; Hutter et al.,
2011).
Although 3H-digoxin is a recommended substrate probe for P-
gp (Rautio et al., 2006; Huang et al., 2007), it has been shown to
be transported by other human transporters as well, especially
the Multidrug Resistance Proteins (MRP) and Organic Anion Trans-
porting Polypeptides (OATP) (Kullak-Ublick et al., 2001; Mikkaichi
et al., 2004; Yamaguchi et al., 2010; Taub et al., 2011). Similarly,
Rh123 has been described as a substrate for MRP1 (Hamilton
et al., 2001), the Breast Cancer Resistance Protein (BCRP) (Doyle
et al., 1998) and OCT (Masereeuw et al., 1997; van der Sandt
et al., 2000). The absence of vectorial transport of 3H-digoxin and
Rh123 in RL-65 cell layers also indicates these other transporters
may not be expressed or functional in the model.
Transport studies were performed in RL-65 cell layers 8 days
after seeding on Transwell inserts. There is currently no standard-
ised time in cultures prior to permeability measurements in hu-
man bronchial epithelial cell layers and these are commonly
conducted in 8–21 day old cell layers. However, there are indica-
tions in the literature which suggest transporter levels in pulmon-
ary in vitro absorption models may be affected by the length in
culture, with an optimal expression and activity achieved after
21 days (Madlova et al., 2009; Haghi et al., 2010; Mukherjee
et al., 2012). Therefore, 8 days in culture may not have been
sufﬁcient for expression of fully functional transporter systems in
RL-65 cell layers. In the culture conditions tested, the layers could
nevertheless not be used for drug transport studies after 9–10 days
on Transwell as the TEER decreased to <200 O cm2 thereafter, be-
fore cells eventually detached from the ﬁlters. There is therefore a
need to prolong the time these can be maintained at an AL inter-
face. For instance, culture on different ﬁlter material or substrate
coatings and optimisation of the medium composition may im-
prove the usefulness of the model as a pre-clinical permeability
screening tool.5. Conclusion
The RL-65 cell line was successfully grown at an air–liquid
interface in a deﬁned serum-free medium for 8 days. RL-65 layers
exhibited suitable absorption barrier properties including TEER
and paracellular permeability in the same range as established hu-
man bronchial epithelial models. Furthermore, they expressed
transporters present in the native epithelium, although their func-
tional activity was not demonstrated. This initial study indicated
that, following further optimisation of the culture conditions, RL-
65 cell layers may offer a valuable in vitro model for permeability
screening in rats and assist in the evaluation of interspecies differ-
ences in pulmonary drug absorption.Acknowledgements
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